Will Go is the Co-founder and Chief Medical Officer of AIHME, “AIM”. The AIHME team is composed of seasoned biotech professionals with deep expertise and a proven industry track record, delivering insights and strategies that drive meaningful impact.

Will has over 20 years of Phase 1–4 experience in academia and the biotech/pharma industry, focusing on novel biomarker and platform-driven drug development.

During his tenure at Kite Pharma, he led the pivotal ZUMA-1 trial and the FDA/EMA approvals of YESCARTA®, the first CAR T-cell therapy for large B-cell lymphoma, which won the 2018 Prix Galien Award. He led the global clinical filings and was instrumental in the launch of YESCARTA®. He also oversaw clinical development as Vice President at Kite/Gilead in the large B-cell lymphoma space.

Subsequently, Will served as Chief Medical Officer at A2 Bio, leading the development of T-cell therapies using the company’s logic-gated CAR T platform to target solid tumors. Under his leadership, A2 Bio raised over $350 million and launched three Phase 1 studies across pancreatic, colorectal, lung, breast, and ovarian cancers, achieving clinical responses in pancreatic and lung cancer.

Earlier in his career, Will played a key role in the global label extension of Vectibix® and the development of extended RAS next-generation sequencing testing in colorectal cancer to identify predictive biomarkers at Amgen.

He earned a B.S. in Biology from Carleton College, followed by an M.D. and Ph.D. through the UC San Diego Medical Scientist Training Program. He completed his internal medicine residency at UCSD School of Medicine and a hematology/oncology fellowship at the UCSD Moores Cancer Center. He was awarded fellowships from CIRM and AACI for tumor immunology research.